To test the efficacy of the compound in vivo, we first induced BRAF mutant melanoma tumors with topical tamoxifen in Tyrosinase:: CreERT2; BrafCA/+; Ptenfl/fl;RhoJ+/+ animals at post-natal day 21 (P21), as described in our other publication (Ruiz et al., 2017), and treated the mice with ARN22089 for 10 days using a twice a day (BID) intraperitoneal (i.p.)dosing regimen. This evidence concerns the gene RHOJ and melanoma.